1st and only VMAT2 inhibitor approved for both TD and HD chorea1

AUS-45561

COMING SOON

ONCE-DAILY DOSING with EXTENDED-RELEASE FORMULATION

Before you prescribed AUSTEDO for his tardive dyskinesia (TD), he was concerned about people noticing his movements.1

Now expressing
himself is
what moves him

*Symptom control defined as change in AIMS total score observed as early as Week 2 in placebo-controlled studies.5

Mechanism of Action:

VMAT2 inhibition can help regulate dopamine function.6

AIMS, Abnormal Involuntary Movement Scale; HD, Huntington’s disease; VMAT2, vesicular monoamine transporter 2.

REFERENCES: 1. AUSTEDO® (deutetrabenazine) tablets current Prescribing Information. Parsippany, NJ: Teva Neuroscience, Inc. 2. Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4(8):595-604. 3. Hauser RA, Barkay H, Fernandez HH, et al. Long-term deutetrabenazine treatment for tardive dyskinesia is associated with sustained benefits and safety: a 3-year, open-label extension study. Front Neurol. 2022;13:773999. doi:10.3389/fneur.2022.773999 4. Marder SR, Singer C, Lindenmayer J-P, et al. A phase 3, 1-year, open-label trial of valbenazine in adults with tardive dyskinesia. J Clin Psychopharmacol. 2019;39(6):620-627. 5. Data on file. Parsippany, NJ: Teva Neuroscience, Inc. 6. Solmi M, Pigato G, Kane JM, Correll CU. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018;12:1215-1238.